PMC

CDN1163 reduces lipid accumulation and decreases lipogenesis in obese mice livers. A, lipid accumulation measured with H&E (top) and Oil red O staining (bottom) in the liver of lean, vehicle-treated obese (Obese) and CDN1163-treated obese (Obese+CDN) mice (n = 5). qRT-PCR analysis of genes involved in liver de novo lipogenesis (B) and lipid oxidation (C) in obese (Ob) versus obese plus CDN1163 (Ob+CDN) mice. Bar, 50 μm. Data are expressed as the means ± S.E. (n = 5). #, p < 0.05; ##, p < 0.01; ###, p < 0.001, obese versus CDN1163-treated obese mice. All determinations were performed on harvested liver tissues at the end of the study (i.e. day 50).

CDN1163 improves mitochondrial efficiency in the liver of ob/ob mice. All determinations were performed on harvested liver tissues at the end of the study (i.e. day 50). qRT-PCR analyses of genes involved in mitochondrial biosynthesis (A) and mitochondrial DNA contents (B). C, Western blot analyses and quantification of proteins involved in OXPHOS and qRT-PCR analyses of OXPHOS genes (D), ATP content (E), and antioxidant enzymes (G) in vehicle (Ob)- versus CDN1163-treated obese (Ob+CDN) mice. F, AMPK phosphorylation (pAMPK) and densitometry (normalized to total AMPK (tAMPK)) in liver samples from lean, vehicle-treated (Ob) versus CDN1163-treated obese (Ob-CDN) mice. GAPDH is a loading control. Data are expressed as the means ± S.E. from at least three experiments; #, p < 0.05 and ##, p < 0.01 obese versus CDN-treated obese mice; **, p < 0.01 versus lean and ***, p < 0.001 CDN1163 versus vehicle.

CDN1163 relieves ER stress and attenuates apoptosis in the liver of ob/ob mice. Shown are Western blot analyses and densitometry quantification of ER stress markers (A) and qRT-PCR analyses of ER chaperones in vehicle-treated obese (Ob) versus CDN1163-treated obese (Ob+CDN) mice (C). B, determination and quantification of spliced (s) and unspliced (u) XBP1 in lean (L), vehicle-treated obese (O), and CDN1163-treated obese (OC) mice. D, TUNEL staining of apoptotic cells in liver tissues from vehicle-treated obese (ob/ob-vehicle) versus CDN1163-treated obese (ob/ob-CDN1163) mice (bar = 50 μm) and quantification of apoptosis shown as a percentage of apoptotic nuclei (red by TUNEL) versus total nuclei (blue by DAPI) (n = 5). E, representative Western blot analyses and quantification of apoptosis markers in liver tissues from vehicle-treated obese (Ob) versus CDN1163-treated obese (Ob+CDN) mice. Data are expressed as the means ± S.E. from at least 3–5 determinations. **, p < 0.01, lean versus obese; #, p < 0.05, ##, p < 0.01, and *, p < 0.05, obese versus CDN1163-treated obese mice. All determinations were performed on harvested liver tissues at the end of the study (i.e. day 50).

Schematic diagram depicting proposed molecular mechanism underlying CDN1163/SERCA2b metabolic benefits. A fundamental abnormality of obesity and diabetes is down-regulation and dysfunction of Serca2b causing intracellular Ca²⁺ imbalance with a concomitant induction of ER stress and mitochondrial dysfunction, as these two events are reciprocally related. ER stress and mitochondrial dysfunction then trigger insulin resistance and development of diabetes. Pharmacological restoration of Serca2b activity by CDN1163 (a) normalizes intracellular Ca²⁺ dyshomeostasis (which reestablishes ER homeostasis) and (b) activates AMPK, which in turn up-regulates PGC1α (which improves mitochondrial biogenesis) and down-regulates HNF4α leading to suppression of gluconeogenesis. Evidence also shows that AMPK can improve ER stress and Ca²⁺ and has long played a major role in mitochondria (dashed lines). Attenuation of gluconeogenesis and ER stress and improvement of mitochondrial efficiency altogether then ameliorate insulin resistance and diabetes.

CDN1163 improves glucose homeostasis and metabolic parameters in ob/ob mice. CDN1163 was administrated for 5 consecutive days (D0 to D4). A, fasting blood glucose levels after first injection of CDN1163 at day 1 (D1). Fasting blood glucose levels (B) and body weight (C) were determined weekly until day 50. D, average food intake in lean, vehicle-treated obese (Ob) and CDN1163-treated obese (Ob+CDN) mice (n = 10/group). E, body composition analyzed for 7 days in a separate cohort (n = 8) before and after 5 days of CDN1163 treatment in vehicle-treated obese (Ob) and CDN1163-treated obese (Ob+CDN) mice. Indirect calorimetry conducted for the last 4 days was assessed oxygen consumption (F), respiratory exchange ratio (RER) (G), and physical activity and caloric intake (H). J, mRNA expression of UCP1, UCP2, and UCP3 in brown tissue in lean, vehicle-treated obese (Ob) and CDN1163-treated obese (Ob+CDN) mice (n = 5). I, glucose levels and body weight after CDN1163 treatment of lean mice. CDN1163 was administrated for 5 consecutive days (D0 to D4). Fasting blood glucose levels and body weight were determined weekly until day 30 in lean plus vehicle (LN+Veh) and lean plus treatment (LN+CDN) mice (n = 6/group). Body weight values for day 1 (D1) and day 31 (D31) are shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001, lean versus obese; #, p < 0.05; ##, p < 0.01; ###, p < 0.001, obese versus CDN1163-treated obese mice.

CDN1163 is an allosteric activator of SERCA2b and enhances Ca²⁺ transport activity in the liver of obese mouse. A, chemical structure of CDN1163 SERCA activator (patents on file). B, the Ca²⁺-ATPase V_max (limiting activity at 10 μm Ca²⁺) was measured in ER vesicles from liver tissue after 20 min of incubation in the presence of various concentrations of CDN1163 as indicated (n = 6). C, effect of CDN1163 on ER Ca²⁺ accumulation in HEK cells that were either transfected with an adenovirus encoding Serca2b (Ad.Serca2b, multiplicity of infection 50) versus control or treated with CDN1163 (10 μm) versus vehicle from a minimum of three determinations. A representative of Western blot of Serca2b expression is shown. *, p < 0.05; and **, p < 0.01 versus control. D, CDN1163 rescues cells from ER stress-induced cell death. ER stress-induced cell death was assessed in HEK cells either untreated or treated with vehicle (DMSO) or with hydrogen peroxide (H₂O₂) in the presence or absence of 10 μm CDN1163 using CellTiter-Glo® luminescent cell viability assay. The data are expressed as the mean ± S.E. from at least three determinations. *, p < 0.05 versus H₂O₂; **, p < 0.01versus vehicle. E, SERCA2b Ca²⁺ transport activity in vivo. Ca²⁺-ATPase activity (left) and the rate of Ca²⁺ uptake (right) were determined in liver ER microsomes purified from vehicle-treated obese (Ob) or CDN1163-treated obese mice (Ob+CDN) after treatment with 50 mg/kg CDN1163 for 5 days (n = 5 animals/group). Data are expressed as the means ± S.E. #, p < 0.05, obese versus CDN1163-treated obese mice.

CDN1163 increases glucose tolerance in ob/ob mice. A, intraperitoneal glucose tolerance test (GTT) assessed on day 8 in lean, vehicle-treated obese (Ob) and CDN1163-treated obese (Ob+CDN) mice (n = 10/group); glucose was measured at times shown after 1 g/kg of glucose injection and calculated as the area under the curve (AUC). B, the intraperitoneal insulin tolerance test was assessed on day 11 after 1 IU/kg of insulin injection 2 h after CDN injection, and glucose clearance is expressed as % reduction from basal levels, and (B) plasma insulin levels at end of study (day 50) are shown for lean and vehicle- and CDN1163-treated obese mice (n = 10) (C). D, representative from at least three experiments of Western blot analysis of insulin-stimulated Akt phosphorylation at serine 473 (pS-Akt) and threonine 308 (pT-Akt) in the liver after an acute insulin bolus (36.3 μg/ml in 0.9% saline (1 units/kg, assuming potency of 27.5 units/mg)). Protein loading was verified with total Akt and GAPDH. Also shown is Western blot liver SERCA2b expression in the three different groups of mice with GAPDH as a loading control. E, quantitative real-time PCR analysis of genes involved in gluconeogenesis in the liver in vehicle-treated obese (Ob) and CDN1163-treated (Ob+CDN) mice. Data are expressed as the means ± S.E. from at least 3–5 determinations. *, p < 0.05; **, p < 0.01; ***, p < 0.001, lean versus obese; #, p < 0.05 and ###, p < 0.001, obese versus CDN1163-treated obese mice. Data in C–E were performed at the end of the study (i.e. day 50). G6Pase, glucose-6-phosphatase.